If you thought these 2 big Nasdaq winners were done, think again

On a strong day for the Nasdaq, two highfliers stood out.

| More on:
woman receiving covid 19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Volatility has returned to the stock market, but finally, the Nasdaq Composite (NASDAQINDEX: ^IXIC) is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today, the Nasdaq was higher by three-quarters of a percent.

It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.

More moves for Moderna and BioNTech

Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.

The general sentiment toward BioNTech and Moderna has been positive because of just how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.

In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday, BioNTech said that it had received provision approval of its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and Pfizer (NYSE: PFE) for more vaccine doses as well.

More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.

Will existing vaccines be enough?

The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, the Delta variant has proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.

For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.

If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A circle of hands from business leads cupping a green leaf in soil, indicating ASX companies embracing the concept of ESG and sustainable business practices
International Stock News

Investors are leaning away from ESG investing, but here’s why you shouldn’t follow the crowd

Don't lose sight of the long-term benefits of ESG.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
International Stock News

3 great foreign companies to invest in right now

There is a world of opportunity in international stocks.

Read more »

man and woman looking at bitcoin mining
International Stock News

This company profited $2.6 billion from crypto. What is it investing in now?

Intercontinental Exchange made some whopper profits from crypto investments. Its recent investment in Black Knight could completely transform the company.

Read more »

happy business people celebrate, share rise, record price, increase
International Stock News

2 cryptos that could lead the market recovery

Bitcoin and Ethereum are uniquely positioned to lead the entire crypto market higher in 2022.

Read more »

A young couple look upset as they use their phones.
International Stock News

Not a risk taker? Here’s how that may cost you in retirement

With no risk comes little to no reward.

Read more »

woman working on tablet
International Stock News

3 top US tech stocks that could help make you rich by retirement

Buying and holding these three technology stocks can help grow your portfolio by leaps and bounds.

Read more »

A piggy bank blasts off into the sky.
International Stock News

Why cryptocurrency EOS soared 19% while the market took a breather today

The move follows a positive court ruling over a settlement tied to allegations of unregistered security sales.

Read more »

A worried man holds his head and look at his computer.
International Stock News

Why Bitcoin, Ethereum, and Dogecoin are slumping today

High correlation to equity markets is back, with the price action for major cryptos closely tracking major indices.

Read more »